WEBULL
WebtradeDownload

Is agilon health (AGL) Undervalued After Revenue Growth And Value Based Care Gains?

Simply Wall St · 2d ago

Recent commentary around agilon health (AGL) has focused on its annual revenue and earnings growth, as well as its efforts to move primary care physicians into value-based Medicare models that rely on long-term partnership structures.

Recent share price action for agilon health has been choppy, with the stock down 3.76% on a 1-day share price basis and 5.06% over 30 days, yet still posting a very large year-to-date share price gain of 405.46% that aligns with a 254.70% 1-year total shareholder return. That rally contrasts with a 34.44% decline over 90 days and deep 3-year and 5-year total shareholder return declines of 82.39% and 85.64%. This suggests that recent enthusiasm around the value-based care model and reported revenue and earnings growth is rebuilding momentum after a difficult longer-term run.

Scan other value-based care and quality-focused opportunities by reviewing the hand picked list of solid balance sheet and fundamentals (25 results) that align with the kind of fundamentals investors are watching at agilon health.

agilon health has swung from deep multi year losses to a very large year to date surge. Is that move really tracking the underlying Medicare platform, or mostly a reset in sentiment that the current share price now needs to justify through valuation?

Most Popular Narrative: 28% Undervalued

The most followed narrative on agilon health puts fair value around $118.33 per share, versus a last close of $85.12. The gap investors are debating is substantial and rooted in the Medicare platform story rather than short term price swings.

Expansion of clinical pathways, successful scaling of chronic disease management programs, and strong PCP and patient retention reinforce agilon health's operational leverage, supporting expectations for durable earnings growth, enhanced gross margin, and improved operating cash flow as the platform scales.

See why 10 investors see agilon health as 28% undervalued.

Result: Fair Value of $118.33 (UNDERVALUED)

Still, concentration in a few payer relationships and recent leadership turnover at agilon health could quickly challenge the 28% undervalued narrative if renegotiations or execution slip.

Find out about the key risks to this agilon health narrative.

Next Steps

Mixed sentiment around agilon health is clear, with investors weighing both enthusiasm and concern. Move quickly to review the underlying data and shape your own view using the 3 key rewards and 1 important warning sign.

Looking for more ideas beyond agilon health?

If you stop your research with agilon health, you risk missing other compelling setups that could better match your risk tolerance and return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.